TK inhibitors
Roche EGFR Mutation Test Approved by FDA as Companion Diagnostic for NSCLC
Roche's real-time PCR test detects defined mutations of the epidermal growth factor receptor gene in DNA from non-small cell lung cancer patients.
JAVELIN Biomarker Analysis Identifies New Kidney Cancer Features Linked to Immunotherapy Response
The study found immunomodulatory and angiogenesis gene expression signatures, mutational profiles, and HLA types could help predict how patients respond to therapy.
FDA Accepts Bridge Biotherapeutics' Investigational New Drug Application for Lung Cancer Drug
BBT-176, a novel agent designed to inhibit EGFR with C797S mutations, will start first-in-human studies in NSCLC this year.
TKI, Anti-VEGF Drug Combo Does Not Delay EGFR-Mutant NSCLC Progression in Phase II Trial
Progression-free survival times were comparable for EGFR-mutated non-small cell lung cancer cases treated with a combination of erlotinib and bevacizumab treatment or erlotinib.